Dr Rebecca Lim, Director of Scientific Affairs at Prescient Therapeutics (ASX: PTX), presented at the fifth annual Cell
Australian biotech company Prescient Therapeutics has achieved numerous milestones in the past financial year as it advances the
Prescient Therapeutics has announced that a global expert in brain cancer, Professor Donald M. O’Rourke, will be joining
Researchers at the University of Pennsylvania (Penn) are developing a new way for cancer-fighting CAR-T cells to overcome
Prescient Therapeutics (ASX: PTX) CEO and MD Steven Yatomi-Clarke discusses the encouraging progress through clinical trials of Prescient’s
Prescient Therapeutics (ASX: PTX) is focused on developing novel, personalised therapies for a range of cancers.
Australian biotech company Prescient Therapeutics has successfully finished a round of safety testing on its PTX-100 drug in
The US Food and Drug Administration has assigned a fast track designation to a new CAR-T cancer treatment